Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Secondary Hyperparathyroidism Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Secondary Hyperparathyroidism Overview | 8 | 1 |
| Secondary Hyperparathyroidism Therapeutics under Development by Companies | 9 | 1 |
| Secondary Hyperparathyroidism Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Secondary Hyperparathyroidism Products under Development by Companies | 13 | 1 |
| Secondary Hyperparathyroidism Companies Involved in Therapeutics Development | 14 | 4 |
| Amgen Inc. | 14 | 1 |
| Deltanoid Pharmaceuticals Inc. | 15 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 16 | 1 |
| OPKO Health, Inc. | 17 | 1 |
| Secondary Hyperparathyroidism Therapeutics Assessment | 18 | 9 |
| Assessment by Monotherapy Products | 18 | 1 |
| Assessment by Target | 19 | 2 |
| Assessment by Mechanism of Action | 21 | 2 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| Drug Profiles | 27 | 16 |
| Calcimimetic-18 Drug Profile | 27 | 1 |
| CTA-091 Drug Profile | 28 | 1 |
| CTAP-201 Drug Profile | 29 | 1 |
| DP-001 Drug Profile | 30 | 1 |
| etelcalcetide hydrochloride Drug Profile | 31 | 5 |
| lunacalcipol Drug Profile | 36 | 2 |
| MT-4580 Drug Profile | 38 | 2 |
| VS-105 Drug Profile | 40 | 1 |
| VS-110 Drug Profile | 41 | 1 |
| VS-411 Drug Profile | 42 | 1 |
| Secondary Hyperparathyroidism Dormant Projects | 43 | 1 |
| Secondary Hyperparathyroidism Discontinued Products | 44 | 1 |
| Secondary Hyperparathyroidism Product Development Milestones | 45 | 11 |
| Featured News &Press Releases | 45 | 1 |
| May 24, 2016: ONO Announces Results from Phase 1/2 and Phase 3 Clinical Studies of Etelcalcetide Hydrochloride (ONO-5163) in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan at ERA-EDTA Congress | 45 | 1 |
| Jan 26, 2016: Investigational Agent Shows Promise for SHPT in Hemodialysis Patients | 45 | 1 |
| Jan 14, 2016: ONO Submits Manufacturing and Marketing Approval Application in Japan for Etelcalcetide Hydrochloride (ONO-5163), a Calcimimetic Agent, for Secondary Hyperparathyroidism in Patients on Hemodialysis | 46 | 1 |
| Dec 01, 2015: Kyowa Hakko Kirin Announces Commencement of Phase 3 Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan | 46 | 1 |
| Nov 07, 2015: Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis | 47 | 1 |
| Nov 06, 2015: FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide | 48 | 1 |
| Sep 02, 2015: Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency | 49 | 1 |
| Aug 25, 2015: Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide | 49 | 1 |
| May 29, 2015: Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease | 50 | 1 |
| Feb 25, 2015: Amgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis | 51 | 1 |
| Oct 15, 2014: Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis | 52 | 1 |
| Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan | 53 | 1 |
| Aug 18, 2014: Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis | 53 | 1 |
| Jan 06, 2012: KAI Pharmaceuticals Announces Initiation Of Second Phase II Study Of KAI-4169 | 54 | 1 |
| Nov 14, 2011: KAI Announces Results from Phase II study of ONO-5163/KAI-4169, Calcium Sensing Receptor Agonist | 54 | 2 |
| Appendix | 56 | 2 |
| Methodology | 56 | 1 |
| Coverage | 56 | 1 |
| Secondary Research | 56 | 1 |
| Primary Research | 56 | 1 |
| Expert Panel Validation | 56 | 1 |
| Contact Us | 56 | 1 |
| Disclaimer | 57 | 1 |